Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
- PMID: 20870345
- DOI: 10.1016/j.ultrasmedbio.2010.07.005
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
Abstract
There is a need for noninvasive methods to detect liver steatosis, which can be a factor of liver fibrosis progression. This work aims to evaluate a novel ultrasonic controlled attenuation parameter (CAP) devised to target, specifically, liver steatosis using a sophisticated process based on vibration control transient elastography (VCTE™). CAP was first validated as an estimate of ultrasonic attenuation at 3.5 MHz using Field II simulations and tissue-mimicking phantoms. Performance of the CAP was then appraised on 115 patients, taking the histological grade of steatosis as reference. CAP was significantly correlated to steatosis (Spearman ρ = 0.81, p < 10(-16)). Area under receiver operative characteristic (ROC) curve (AUC) was equal to 0.91 and 0.95 for the detection of more than 10% and 33% of steatosis, respectively. Furthermore, results show that CAP can efficiently separate several steatosis grades. These promising results suggest that CAP is a noninvasive, immediate, objective and efficient method to detect and quantify steatosis.
Copyright © 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.Ultrasound Med Biol. 2016 Jan;42(1):92-103. doi: 10.1016/j.ultrasmedbio.2015.08.008. Epub 2015 Sep 19. Ultrasound Med Biol. 2016. PMID: 26386476
-
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.Liver Int. 2012 Jul;32(6):902-10. doi: 10.1111/j.1478-3231.2012.02781.x. Epub 2012 Mar 21. Liver Int. 2012. PMID: 22435761
-
How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.Liver Int. 2014 Jul;34(6):e111-7. doi: 10.1111/liv.12305. Epub 2013 Sep 4. Liver Int. 2014. PMID: 24034415
-
The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):13-20. doi: 10.1016/j.clinre.2011.08.001. Epub 2011 Sep 15. Clin Res Hepatol Gastroenterol. 2012. PMID: 21920839 Review.
-
Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC Gastroenterol. 2019 Apr 8;19(1):51. doi: 10.1186/s12876-019-0961-9. BMC Gastroenterol. 2019. PMID: 30961539 Free PMC article.
Cited by
-
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.Wien Klin Wochenschr. 2021 May;133(9-10):441-451. doi: 10.1007/s00508-020-01735-5. Epub 2020 Sep 15. Wien Klin Wochenschr. 2021. PMID: 32930860 Free PMC article. Clinical Trial.
-
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.J Hepatol. 2016 Nov;65(5):1006-1016. doi: 10.1016/j.jhep.2016.06.005. Epub 2016 Jun 14. J Hepatol. 2016. PMID: 27312947 Free PMC article. Review.
-
Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals.Rom J Morphol Embryol. 2023 Oct-Dec;64(4):483-491. doi: 10.47162/RJME.64.4.04. Rom J Morphol Embryol. 2023. PMID: 38184828 Free PMC article.
-
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.Liver Int. 2019 Jan;39(1):127-135. doi: 10.1111/liv.13943. Epub 2018 Sep 22. Liver Int. 2019. PMID: 30107095 Free PMC article.
-
Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study.Gastroenterol Res Pract. 2019 Nov 13;2019:5647161. doi: 10.1155/2019/5647161. eCollection 2019. Gastroenterol Res Pract. 2019. PMID: 31827504 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous